Novel anti-cancer agents in development: exciting prospects and new challenges.
Novel anti-cancer agents in development: exciting prospects and new challenges.
复制标题
DOI：
10.1053/ctrv.1999.0134
复制
发表时间：
1999-10
影响因子：
11.8
通讯作者：
L. Seymour
中科院分区：
文献类型：
--
作者：
L. Seymour
大量的癌症化疗药物正在开发中，许多已经进行了临床试验。其中许多化合物被设计用于调节或抑制分子靶点，这些分子靶点已被确定为对癌症的发展或控制至关重要。抑制的靶点包括基质金属蛋白酶、信号转导的介体(酪氨酸激酶、细胞周期蛋白依赖性激酶和其他激酶，如蛋白激酶C和A)，以及ras的表达和预烯基化。潜在的抑制性化合物包括小分子、人源化的单抗或反义寡核苷酸。这些化合物中的许多在开发方面都相对先进。在一些情况下已经证明了原则证据，至少有一种这种化合物已获准使用。虽然这些新化合物提供了令人兴奋的机会，但在选择适当的试验设计和替代终点方面，许多化合物带来了真正的挑战。
A large number of cancer chemotherapeutic agents, are in development, many already undergoing clinical testing. A number of these compounds were designed either to modulate or inhibit molecular targets which have been identified as being critical to the development or control of cancer. Targets for inhibition include matrix metalloproteinases, mediators of signal transduction (tyrosine kinases, cyclin dependent kinases and other kinases such as protein kinase C and A) as well as ras expression and prenylation. Classes of potential inhibitory compounds include small molecules, humanized monoclonal antibodies or antisense oligonucleotides. Many of these compounds are relatively well advanced in development. Proof of principle has already been demonstrated in some instances and at least one such compound has been approved for use. Although these new compounds offer exciting opportunities, many bring with them real challenges in terms of the selection of appropriate trial design and surrogate end-points.